Peptides as cancer vaccines.

Calvo Tardón M; Allard M; Dutoit V; Dietrich PY; Walker PR

doi:10.1016/j.coph.2019.01.007

Back

Journal article

Peptides as cancer vaccines.

Calvo Tardón M Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Allard M Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Dutoit V Center for Translational Research in Onco-Hematology, Department of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Dietrich PY Center for Translational Research in Onco-Hematology, Department of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Walker PR Center for Translational Research in Onco-Hematology, Division of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland. Electronic address: Paul.Walker@unige.ch.

2019-03-05

Published in:

Current opinion in pharmacology. - 2019

English Cancer vaccines based on synthetic peptides are a safe, well-tolerated immunotherapy able to specifically stimulate tumor-reactive T cells. However, their clinical efficacy does not approach that achieved with other immunotherapies such as immune checkpoint blockade. Nevertheless, major advances have been made in selecting tumor antigens to target, identifying epitopes binding to classical and non-classical HLA molecules, and incorporating these into optimal sized peptides for formulation into a vaccine. Limited potency of currently used adjuvants and the immunosuppressive tumor microenvironment are now understood to be major impediments to vaccine efficacy that need to be overcome. Rationally designed combination therapies are now being tested and should ultimately enable peptide vaccination to be added to immuno-oncology treatment options.

Language